FindTrial
Sign In

In vitro study of Cefuroxime-Clavulanic Acid

In vitro Susceptibility of Clinical Isolates to Cefuroxime-Clavulanic Acid - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/01/061197
Enrollment
100
Registered
2024-01-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A498- Other bacterial infections of unspecified site

Interventions

Intervention1: NIL: NIL

Sponsors

Mankind Pharma Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Clinical isolates from non-repetitive clinical samples (such as blood, urine, pus, sputum, etc.) 2. Successful evaluation of Minimum Inhibitory Concentration (MIC)

Exclusion criteria

Exclusion criteria: 1. Isolates from repeat cultures of the same clinical sample 2. Non-fermenters or non-fermenting bacteria

Design outcomes

Primary

MeasureTime frame
To evaluate in vitro susceptibility of clinical isolates to cefuroxime-clavulanic acid based on Minimum Inhibitory Concentration (MIC)Timepoint: Baseline—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Saher Khan

Mankind Pharma Limited

drprashant.agrawal@mankindpharma.com8108344430

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026